Cost-Effectiveness of Follitropin Delta versus Follitropin Alfa in Controlled Ovarian Stimulation for IVF/ICSI Cycles in China
Moderator
Rui Yan
Speakers
sheng han; Guan Xiaodong, MD; Jérémy CARETTE, PharmD; Marie Markert, MSc, Ferring Pharmaceuticals A/S, Kastrup, Denmark; Lisa Liu; Jie Qiao
OBJECTIVES: Follitropin delta (Rekovelle) is a recombinant follicle-stimulating hormone (rFSH) used in controlled ovarian stimulation (COS) for IVF/ICSI cycles. It is delivered in a pen and offers personalized dosing based on patient's ovarian reserve profile (anti-Müllerian hormone (AMH) levels) and body weight. It provides individualized fixed daily dosing avoiding the need for dose adjustments, while maintaining a favourable safety/efficacy profile. The objective of this analysis is to assess the cost-effectiveness of Rekovelle compared with Gonal-F for women undergoing COS for IVF/ICSI cycles in China.
METHODS: A decision-tree model was developed comparing the outcomes of treatment with Rekovelle versus Gonal-F through ongoing pregnancy (OP) and live birth (LB) in fresh cycles, using data from the pan-Asian GRAPE trial. The analyses were stratified by age and ovarian reserve profile and reflected a single COS cycle. Costs were estimated from the Chinese treatment setting perspective, and uncertainty was assessed through sensitivity analyses.
RESULTS: Rekovelle achieved non-inferiority of OP (31.3% vs 25.7% [diff 5.4% CI: -0.2%;11.0%]) in its individualized dosing regimen compared with Gonal-F in conventional dosing, but significantly higher rate of LB (31.3% vs 24.7% [diff 6.6% CI: 0.9%; 11.9%]; P=0.023) in the GRAPE trial. The mean total dose was 78 µg for Rekovelle versus 110 µg for Gonal-F. In the economic model, the total treatment cycle costs were estimated at ¥25,689 for Rekovelle and ¥27,189 for Gonal-F. Excluding cost of delivery, the total costs were ¥23,255 and ¥25,214, respectively. Hence, Rekovelle was a dominant treatment option. Sensitivity analyses supported the deterministic results, showing >89% probability of Rekovelle being dominant with OP endpoint and >82% probability of being dominant with the LB endpoint.
CONCLUSIONS: Rekovelle is cost-effective compared with Gonal-f in COS for IVF/ICSI cycles in China. This is attributed to improved OP and LB rates with a lower total dose of FSH.
METHODS: A decision-tree model was developed comparing the outcomes of treatment with Rekovelle versus Gonal-F through ongoing pregnancy (OP) and live birth (LB) in fresh cycles, using data from the pan-Asian GRAPE trial. The analyses were stratified by age and ovarian reserve profile and reflected a single COS cycle. Costs were estimated from the Chinese treatment setting perspective, and uncertainty was assessed through sensitivity analyses.
RESULTS: Rekovelle achieved non-inferiority of OP (31.3% vs 25.7% [diff 5.4% CI: -0.2%;11.0%]) in its individualized dosing regimen compared with Gonal-F in conventional dosing, but significantly higher rate of LB (31.3% vs 24.7% [diff 6.6% CI: 0.9%; 11.9%]; P=0.023) in the GRAPE trial. The mean total dose was 78 µg for Rekovelle versus 110 µg for Gonal-F. In the economic model, the total treatment cycle costs were estimated at ¥25,689 for Rekovelle and ¥27,189 for Gonal-F. Excluding cost of delivery, the total costs were ¥23,255 and ¥25,214, respectively. Hence, Rekovelle was a dominant treatment option. Sensitivity analyses supported the deterministic results, showing >89% probability of Rekovelle being dominant with OP endpoint and >82% probability of being dominant with the LB endpoint.
CONCLUSIONS: Rekovelle is cost-effective compared with Gonal-f in COS for IVF/ICSI cycles in China. This is attributed to improved OP and LB rates with a lower total dose of FSH.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE195
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health